Basic net loss per share is calculated by dividing net loss attributable to Class A common stockholders by the weighted-average shares of the Class A common stock outstanding without the consideration for potential dilutive securities. Diluted net loss per share represents basic net loss per share adjusted to include the effects of all potentially dilutive shares. Diluted net loss per share is the same as basic loss per share for all periods as the inclusion of potentially issuable shares would be antidilutive.

The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended June 30, 2026 and 2025 (in thousands, except share and per share amounts):


	Three Months Ended June 30,						For the Six Months Ended June 30,
	2026			2025			2026			2025
Numerator
Net loss	$	(46,436	)	$	(36,965	)	$	(89,057	)	$	(74,917	)
Less: Net loss attributable to noncontrolling interests		(18,014	)		(20,413	)		(40,598	)		(41,631	)
Net loss available to Class A common stockholders of ProKidney Corp., basic and diluted	$	(28,422	)	$	(16,552	)	$	(48,459	)	$	(33,286	)

Denominator
Weighted average shares of Class A common stock of ProKidney Corp. outstanding, basic and diluted		186,560,999			130,730,840			164,366,352			129,858,450
Net loss per share attributable to Class A common stock
Net loss per share attributable to Class A common stock of ProKidney Corp., basic and diluted	$	(0.15	)	$	(0.13	)	$	(0.29	)	$	(0.26	)

Outstanding anti-dilutive securities not included in the diluted net loss per share calculation include the following:


	As of June 30,
	2026		2025
Antidilutive securities
ProKidney Corp. Class B common stock		96,596,315		159,288,931
Unvested Restricted Stock Rights		–		742,684
Earnout Rights		17,500,000		17,500,000
Stock options granted under the 2022 Equity Incentive Plan		39,826,692		30,504,248